Last updated: February 27, 2026
What is NDC 69315-0185 and its Therapeutic Profile?
NDC 69315-0185 is marketed as Zolgensma (onasemnogene abeparvovec-xioi). It is a gene therapy indicated for the treatment of spinal muscular atrophy (SMA) in pediatric populations under two years of age. Approved by the FDA in May 2019, Zolgensma is administered as a one-time intravenous infusion.
Market Size and Demographics
Incidence and Prevalence
- SMA affects approximately 1 in 10,000 live births globally.
- Estimated annual incident cases in the U.S.: 400–500 new patients under age 2 annually.
- Total patient population eligible for treatment in the U.S.: approximately 1,200–1,500 children under age 2.
Market Penetration
- Zolgensma is approved for all SMA types (Type 1, 2, 3), with the highest utilization in severe Type 1 cases.
- Market penetration in the U.S.: approximately 45–50% of eligible patients as of 2023.
- Discounted Access: Several payers require negotiations, impacting the accessible market.
Competitive Landscape
- Spinraza (nusinersen): Approved since 2016; administered multiple times, making market share significant.
- Evrysdi (risdiplam): Approved in 2020; oral formulation improves compliance.
- Zolgensma typically positioned as a one-time treatment with potential long-term benefits.
Pricing and Revenue Projections
Current Pricing
- List Price: $2.1 million per dose (brand name, one-time infusion).
- Actual net price after discounts and negotiations varies, estimated between $1.6 million and $2 million per patient.
- Payer rebates and manufacturer discounts significantly impact net revenue.
Revenue Trends
| Year |
Estimated Patient Access |
Gross Revenue (USD Millions) |
Notes |
| 2021 |
400 |
800 |
Market expansion, increasing uptake |
| 2022 |
450 |
945 |
Additional approvals and increasing access |
| 2023 |
500 |
1,050 |
Greater market penetration, price stabilization |
Future Market and Price Adjustments
- Introduction of biosimilars is unlikely due to the unique nature of gene therapies.
- Payer negotiations may lead to slight discounts over time.
- Potential expansion to older pediatric or adult SMA patients could open new markets, but approvals are pending or under review.
Pricing Risks
- Regulatory discounting pressures to improve affordability.
- Market share erosion due to competition or generics unlikely.
- Manufacturing costs: high, but the one-time treatment model offsets ongoing expenses.
Regulatory and Policy Impact
- Price caps or value-based pricing models could influence future list prices.
- International pricing varies significantly; EU countries tend to see discounts of 20-40% compared to U.S. prices.
- Recent legislative initiatives advocate for price transparency and affordability, potentially impacting future prices.
Key Influences on Price and Market Growth
- Increased diagnosis rates, driven by genetic testing.
- Expansion of indications to treat broader age groups or SMA types.
- Integration of gene therapy into pediatric treatment protocols.
Summary of Price Outlook
| Timeframe |
Price Range (USD) |
Key Factors |
| 2023–2024 |
$1.8M–$2.0M |
Market stabilization, payer negotiations |
| 2025–2027 |
$1.7M–$1.9M |
Market mature, competition minimal, policy impact |
Key Takeaways
- NDC 69315-0185 (Zolgensma) has a list price of approximately $2.1 million, with net revenue estimates around $1.6–$2 million per patient after discounts.
- The market remains constrained by the small SMA pediatric population but shows steady growth through increasing diagnosis and treatment rates.
- Price projections indicate marginal downward adjustments driven by payer negotiations and regulatory pressures.
- Long-term prospects hinge on expanding indications and improving access.
FAQs
Q1: What factors influence Zolgensma’s market penetration?
Market penetration depends on diagnosis rates, payer coverage, and clinician adoption. Early genetic testing and expanded indications further enhance access.
Q2: How does Zolgensma compare cost-wise to rivals?
While Zolgensma’s upfront cost is higher than Spinraza’s and Evrysdi’s cumulative expenses, its one-time administration benefits long-term cost savings and quality of life.
Q3: Are there upcoming regulatory changes expected to impact pricing?
Legislative efforts favoring price transparency and value-based pricing could exert downward pressure.
Q4: Is the market for gene therapies like Zolgensma growing?
Yes. As approval extends to broader indications and older patients, the market size is expected to increase modestly.
Q5: How do international prices compare?
European and Asian markets typically see discounts of 20–40% relative to U.S. prices due to different regulatory and payer systems.
References:
- U.S. Food and Drug Administration. (2019). Zolgensma approval.
- IQVIA. (2023). Top-line gene therapy market analysis.
- Evaluate Pharma. (2023). Gene therapy pricing and market forecasts.
- Industry reports on SMA prevalence and treatment access.
- CMS and U.S. payer policies on high-cost rare disease treatments.
